Themis Medicare Share Price Analysis and Insights
Comprehensive Overview of Themis Medicareâs Current Share Price Landscape
As of July 24, 2025, Themis Medicare is trading at âš118.85 per share. This marks a pronounced shift from the stockâs high-flying days, since just a year ago its 52-week high touched âš317.00, with a 52-week low observed at âš115.00. Such a wide range signals considerable price volatility. Over the past year, Themis Medicare has experienced a staggering drop of more than 60% from its peak, placing the current price just above its 52-week lowâthis proximity to the bottom often intensifies investor concerns about stability and recovery potential.
Recent volatility is readily apparent in the companyâs trailing returns. Weekly performance reveals a decline of -2.12%, while the past month was even more challenging with a -7.18% return. The pain extends further back, showing -11.21% over three months, and a dramatic -51.30% decline in six months. Yearly, the stock is down roughly -46.43%, underscoring the pace and breadth of this correction.
A closer review of trading volumes provides further insight. On July 24, trading activity ranged between 82,340 and 107,048 shares. This aligns with a notable 20% reduction in investor interest compared with the previous month, pointing to diminished enthusiasm and possibly a lack of support from institutional or retail buyers.
Market Capitalization Insights: Positioning Themis Medicare Among Its Peers
Market capitalization (market cap) gives investors context for assessing a company’s size, stability, and liquidity in comparison to its industry peers. As of the latest data, Themis Medicareâs market cap fluctuates between âš1,093.90 Cr and âš1,124.36 Cr. These numbers classify it firmly as a mid-cap pharmaceutical stock within the Indian market.
The table below offers a helpful snapshot of Themis Medicareâs key standings:
| Metric | Current Value | 52-Week Range |
|---|---|---|
| Market Cap (Cr) | âš1,093.90 – âš1,124.36 | N/A |
| Share Price (âš) | âš118.85 | âš115.00 – âš317.00 |
| PE Ratio | 36.33 | 34.10 – 38.39 |
| PB Ratio | 0.34 | 2.84 – 3.79 |
| Return on Equity (ROE) | 9.59% | N/A |
Among mid-sized pharmaceutical players, Themis Medicareâs market cap sits comfortably in the median range. This positioning means its shares generally enjoy reasonable liquidity, but the rapid price declines suggest that investor sentiment is currently more negative compared with select peers, perhaps owed to company-specific or sector-wide developments. While top performers in mid-cap pharma boast more robust mutual fund support and less volatility, Themis Medicare has lagged, as reflected in the trading trends discussed in the Gulshan Medicare analysis.
In-depth Valuation Metrics: PE Ratio, PB Ratio, and Return on Equity Explained
Valuation metrics help investors judge whether a stock is priced attractively or whether risks may be mispriced by the market. As of July 24, 2025, Themis Medicareâs key metrics are:
- PE Ratio: 36.33 (prior figures ranged from 34.10 to 38.39)
- PB Ratio: 0.34 (previously 2.84 and 3.79)
- ROE: 9.59%
PE Ratio (Price to Earnings): At 36.33, this value is high relative to peers and the typical industry average, which often hovers between 20 and 30 for Indian pharmaceutical mid-caps. A high PE can indicate optimism about future growth or, conversely, overvaluation if earnings outlooks deteriorateâa likely interpretation amid declining prices.
PB Ratio (Price to Book): The sharp drop to 0.34 is surprisingly low and signals the market values Themis Medicare under its book valueâthis situation often hints at market skepticism regarding asset quality, profit sustainability, or future growth prospects.
Return on Equity (ROE): At 9.59%, Themis Medicareâs ROE trails some sector leaders but remains in a healthy range for the segment. For context, mid-cap Indian pharma companies often report ROEs in the 10-15% band.
These fundamentals, when viewed collectively, paint a picture of a company currently under pressure, with market pricing that likely builds in expectations of slower profits or operational headwinds going forward. For further clarity on how valuation impacts healthcare plans, you might find it helpful to read about F Plan Medicare and related financial structures.
Understanding Themis Medicareâs Share Price Volatility and Investor Sentiment
The share price currently sits just above its 52-week low, an alarming station given its peak was over âš317.00 within the past year. This translates to a 60%+ fall from peak to trough, inflicting losses on any investor who entered near the top. Contributing factors include:
- Plunging investor activity: Trading volumes have tapered, and retail/institutional engagement is down 20% month-to-month.
- Near-zero mutual fund holdings: Collective assets from sectoral pharma funds in Themis Medicare amount to less than 0.03%, pulling away a potential source of share price support.
- Negative recent returns: The painful -46.43% 1-year return is matched by longer spans of declining performance metrics.
The above factors have prompted a risk-averse mindset among market participants. As is often the case with mid-cap pharma, market psychology can amplify both rises and corrections. Ongoing sectoral headwinds such as pricing controls or regulatory scrutiny fuel this uncertainty, making the recent volatility more severe than usual. For greater insight into share price sensitivity and regulatory context, see our coverage of the Medicare opt out provision’s effect on healthcare business sentiment.
Case Studies and Historical Performance: Learning from the Past
Case Study: The 2024â2025 Price Decline
In August 2024, Themis Medicare shares traded north of âš250. By July 2025, they had slipped to around âš120, reflecting a more than 50% drop in less than a year. This abrupt fall was matched across the Indian mid-cap pharma sector, triggered by a mix of:
- Earnings disappointments in the second half of 2024
- Heightened regulatory scrutiny on pricing and compliance
- Market-wide corrections that hit riskier asset classes particularly hard
During this period, even companies with robust financials were unable to stave off losses, as sectorwide pessimism grew. Importantly, no singular company event (like fraud or bankruptcy) was reported to cause the collapse, meaning broader market factors had an outsized impact.
5-Year Historical Return of +216.15%
Zooming out, Themis Medicareâs five-year return stands at a remarkable +216.15%. Investors who acquired the stock prior to 2020 have witnessed significant wealth creation, even after this yearâs correction. This case emphasizes the dual nature of mid-cap pharma stocks: their high long-term return potential is matched with pronounced risk and volatility. Timing and entry price thus become crucial factors, reinforcing the importance of ongoing market monitoring.
Sectoral and Regulatory Backdrop: Recent Market and Policy Dynamics
According to the most recent information, no direct new tariffs, rules, or regulations have been enacted specifically affecting Themis Medicare. Nevertheless, the broader Indian pharmaceutical market has faced:
- Increased pressure from global pricing controls
- Elevated compliance and reporting requirements
- Sporadic regulatory crackdowns that tend to depress sentiment and cap profit margins
All together, these sectoral issues have weighed on both the share price and the appetite of major investors. Themis Medicare, lacking meaningful mutual fund support, has been particularly susceptible to the mood swings that ripple across the entire industry. For more about the regulatory backdrop in healthcare, our article on the enrollment period for Medicare provides broader policy context that influences companies similar to Themis Medicare.
Key Phrases Frequently Mentioned in Top Articles: What They Reveal About Themis Medicare
A review of high-ranking coverage on Themis Medicare surfaces several recurring key phrases:
- âShare price declineâ and âvolatilityâ headline nearly every major summary
- âMarket capitalizationâ is scrutinized as a gauge of resilience and investor appeal
- âPE ratioâ and âPB ratioâ highlight concerns over valuation and asset quality
- âMutual fund ownershipâ regularly arises, underscoring fears about a thin investor base
- âReturn performanceâ and âhistorical returnsâ serve to balance the discussion, showing that long-term prospects remain strong in spite of recent disappointment
The frequency of these phrases reflects not only the numbers themselves but the deeper market anxiety surrounding Themis Medicareâs future path, especially against the backdrop of sector volatility and uncertain investor sentiment.
Frequently Asked Questions (FAQ) on Themis Medicare Share Price
What are the key factors influencing Themis Medicare’s share price trend?
The dominant factors include sector-wide headwinds (such as regulatory and pricing pressures), lackluster earnings, minimal institutional backing, and reduced investor activityâall contributing to high volatility and a struggling share price.
How does Themis Medicare’s market capitalization compare to its peers?
Themis Medicare falls within the median of Indian pharma mid-caps (âš1,093.90ââš1,124.36 Cr). Peer companies with greater mutual fund support generally exhibit less volatility and better share price recovery during market downturns.
What is the historical performance of Themis Medicare over the last five years?
Despite the recent steep decline, Themis Medicare has posted a five-year return of +216.15%, making it a dramatic long-term outperformer for those who invested well before the latest correction.
How does Themis Medicare’s PE and PB ratios compare to the industry average?
The current PE (36.33) is above mid-cap pharma norms, likely due to collapsing earnings or overvaluation signals, while the PB ratio (0.34) is far below sector benchmarks, signaling skepticism about current assets or future profitability.
What are the recent news and developments affecting Themis Medicare’s stock?
Recently, there have been no direct regulatory or corporate announcements specifically targeting Themis Medicare; the sharp decline instead appears tied to industry-wide factors.
Strategic Takeaways for Investors Considering Themis Medicare
- Risk and Volatility: Caution is warranted given the stockâs proximity to 52-week lows, decreasing volumes, and muted mutual fund interest. Volatility remains high.
- Historical Performance: Early investors have enjoyed strong gains, with a +216.15% five-year return. However, this performance masks substantial recent losses.
- Sector Monitoring: Ongoing changes in regulation, policy, and sector sentiment are crucial for understanding the path forward. Keep an eye on new earnings reports and healthcare updates.
- Liquidity and Funding: Low mutual fund support means the stock may see outsized price swings during thin trading sessions.
In closing, Themis Medicare presents a compelling mix of long-term growth with elevated near-term risk. Investors who prioritize stability should watch for further signs of institutional support and sector recovery. For related topics on market dynamics and healthcare sector analysis, you may be interested in our piece about Medicare wages and tips meaning.
